Virginia Commonwelath University
Welcome,         Profile    Billing    Logout  
 8 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sanyal, Arun J
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
VEDS, NCT04801849: Vitamin E Dosing Study

Active, not recruiting
2
200
US
Vitamin E, d-alpha-tocopherol, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Duke University, Liver Institute Northwest, Indiana University, St. Louis University, University of California, San Diego, University of Southern California, University of California, San Francisco, Virginia Commonwealth University, The Cleveland Clinic
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
03/25
09/25
NCT06095986: A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

Suspended
2
24
US
Aramchol meglumine
Galmed Pharmaceuticals Ltd, Virginia Commonwealth University
Primary Sclerosing Cholangitis
09/26
12/27
LCN RESCU, NCT05832229: Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Recruiting
2
256
US
Rosuvastatin, Rosuvastatin 20 mg, Rosuvastatin 10 mg
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
11/26
11/26
NCT05130346: Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

Withdrawn
N/A
20
US
Mindfulness Based Stress Reduction (MBSR)
Virginia Commonwealth University
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
06/23
12/23
NCT03850899: Alcoholic Hepatitis Network Observational Study

Completed
N/A
1134
US
Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcoholic Hepatitis
06/24
06/24
NCT04054310: Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

Recruiting
N/A
225
US
Liver Multi Scan, Biopsy
Perspectum
NASH - Nonalcoholic Steatohepatitis
05/24
05/24
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT04454463: Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

Active, not recruiting
N/A
1640
US
Johns Hopkins Bloomberg School of Public Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Baylor College of Medicine, Case Western Reserve University, Duke University, Ann & Robert H Lurie Children's Hospital of Chicago, Indiana University, Liver Institute Northwest, Seattle Children's Hospital, St. Louis University, University of California, San Diego, University of California, San Francisco, University of Southern California, Virginia Commonwealth University, Emory University, Children's Hospital Medical Center, Cincinnati
Liver Diseases
06/25
06/25
DPAILO-2, NCT06493253: Digital Pathology and AI for Liver Outcomes in MASLD

Not yet recruiting
N/A
1700
US
Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
PharmaNest, Inc, Nonalcoholic Steatohepatitis Clinical Research Network (NASH), Virginia Commonwealth University
Metabolic Dysfunction-associated Steatotic Liver Disease
08/25
11/25
LCN-C, NCT05740358: Liver Cirrhosis Network Cohort Study

Recruiting
N/A
1200
US
Northwestern University, The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California, Central Virginia Veterans Healthcare System
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
09/27
09/28
NCT03282305: Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese

Not yet recruiting
N/A
5000
NA
Great China Fatty Liver Consortium Limited, Chinese University of Hong Kong, Virginia Commonwealth University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
12/28
12/29

Download Options